Table 2.
Ranking | RefSeq ID | Chromosome | Gene name | EMSAa | ChIP | Transfection |
---|---|---|---|---|---|---|
1b | NM_001708 | chr7 | Opsin 1 (cone pigments), short-wave-sensitive (OPN1SW) | |||
2 | NM_001297 | chr16 | Cyclic nucleotide-gated channel beta 1 (CNGB1) | |||
3 | NM_000541 | chr2 | S-Antigen; retina and pineal gland (arrestin) (SAG) | |||
4c | NM_033028 | chr15 | Bardet–Biedl syndrome 4 (BBS4) | + | ||
5 | NM_000326 | chr15 | Retinaldehyde binding protein 1 (RLBP1) | |||
6 | NM_000283 | chr4 | Phosphodiesterase 6B, rod, beta (PDE6B) | |||
7 | NM_012265 | chr22 | Chromosome 22 open reading frame 3 (C22orf3) | |||
8 | NM_000180 | chr17 | Guanylate cyclase 2D, membrane (retina-specific) (GUCY2D) | + | + | + |
9 | NM_000539 | chr3 | Rhodopsin (opsin 2, rod pigment) (RHO) | |||
10 | NM_000330 | chrX | Retinoschisis (X-linked, juvenile) 1 (RS1) | |||
11 | NM_001604 | chr11 | Paired box gene 6 (aniridia, keratitis) (PAX6) | |||
12 | NM_002900 | chr10 | Retinol binding protein 3, interstitial (RBP3) | |||
13 | NM_006269 | chr8 | Retinitis pigmentosa 1 (autosomal dominant) (RP1) | + | + | + |
14d | NM_000440 | chr5 | Phosphodiesterase 6A, cGMP-specific, rod, alpha (PDE6A) | |||
15 | NM_000350 | chr1 | ATP-binding cassette, sub-family A (ABC1), member 4 (ABCA4) | + | + | + |
16 | NM_004312 | chrX | Arrestin 3, retinal (X-arrestin) (ARR3) | + | + | |
17 | NM_014848 | chr15 | Synaptic vesicle protein 2B homolog (SV2B) | |||
18 | NM_007123 | chr1 | Usher syndrome 2A (autosomal recessive, mild) (USH2A) | |||
19 | NM_006493 | chr13 | Ceroid-lipofuscinosis, neuronal 5 (CLN5) | |||
20 | NM_022567 | chrX | Nyctalopin (NYX) | |||
21 | NM_005272 | chr1 | Guanine nucleotide binding protein (G protein), (GNAT2) | |||
22 | NM_002574 | chr1 | Peroxiredoxin 1 (PRDX1) | |||
23 | NM_005316 | chr11 | General transcription factor IIH, polypeptide 1 (GTF2H1) | |||
24 | NM_000253 | chr4 | Microsomal triglyceride transfer protein (MTP) | |||
25 | NM_000409 | chr6 | Guanylate cyclase activator 1A (retina) (GUCA1A) |
aPositive results from each experiment are marked with ‘+’.
bThe positive controls are highlighted by italics.
cThe genes selected for experimental validation are in bold font.
dThis gene was not selected as positive control in our analysis, but has been found to be CRX target recently (52).